StockDuty ← Dashboard Aug 26, 2026 06:35 AM ET
SignalFDA/Bio

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Week 104 pivotal trial data and ISDS 2026 presentation signal key efficacy milestone.

What changed
Why it matters
Week 104 pivotal trial data and ISDS 2026 presentation signal key efficacy milestone.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →